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Abstract
Purpose To evaluate the change in visual
function after starting glaucoma treatment and
correlate this to a decrease in intraocular
pressure (IOP) in primary open-angle
glaucoma patients.
Methods A prospective, randomized clinical
trial was carried out involving 54 glaucoma
patients (54 eyes). After inclusion, patients
randomly received timolol maleate 0.5%,
brimonidine tartrate 0.2%, or travoprost 0.004%
in one randomly selected eye. Patients
underwent Goldmann applanation tonometry,
visual acuity test, standard automated
perimetry (SAP), visual quality perception test
(visual analogue scale), and contrast
sensitivity (CS) test, in a random order before
and after the 4-week glaucoma treatment.
Results There were statistically significant
changes in IOP (mean change [standard
deviation], 7.8 [3.6] mmHg, Po0.001), SAP
mean deviation index (0.84 [2.45] dB, P¼ 0.02),
visual quality perception (0.56 [1.93],
P¼ 0.045), and CS at frequencies of 12 cycles/
degree (0.10 [0.37], P¼ 0.03) and 18 cycles/
degree (0.18 [0.42], P¼ 0.02) after the 4-week
treatment when compared with baseline. No
statistically significant differences were found
between the treatment groups in visual
function changes after treatment (P40.40). No
significant correlations between IOP reduction
and changes in visual function were found
(P40.30).
Conclusions Visual quality perception,
visual field mean deviation index, and CS
at higher frequencies improve after
starting glaucoma therapy. However, no
correlation was found between IOP
reduction and changes in visual function, and
no differences were found in visual function
when the three medications studied were
compared.
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Introduction
Primary open-angle glaucoma (POAG) is the
most common type of glaucoma. Recent
projections estimate that approximately 60.5
million people will have glaucoma worldwide
in 2010. POAG will be responsible for 74% of
these cases.1 Elevated intraocular pressure (IOP)
is a major risk factor for this disease, which is
characterized by retinal ganglion cell
degeneration, optic nerve head changes, and
vision loss.2,3
The glaucomatous damage to visual function
has been considered irreversible.4 However,
several studies have reported partial recovery
from visual field defects in some patients, which
is related to the IOP reduction achieved in each
eye.5–8
During the natural course of glaucomatous
optic neuropathy (GON), certain types of
functional vision loss may occur earlier than
those detected by standard automated
perimetry (SAP).4,9 Alterations in contrast
sensitivity (CS) have been observed before any
visible nerve fiber layer damage or SAP visual
field defects.10,11 CS alterations have also been
shown to precede significant visual acuity
loss.12 Several studies have reported an
improvement of CS in glaucoma patients after
treatment with topical beta-blockers,13
alpha-agonists,2 carbonic anhydrase
inhibitors,14 or surgical reduction of IOP.4
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Most studies concerning changes in visual function in
POAG have limited sample sizes and the results are
controversial.2,3,15,16 This prospective study was
conducted to investigate changes in visual function
related to IOP reduction after treating POAG patients
with antiglaucoma medications.
Material and methods
A prospective, randomized clinical trial was conducted
involving 54 POAG patients (54 eyes) from the Federal
University of Sa˜o Paulo, Brazil. The protocol adhered to
the tenets of the Declaration of Helsinki and was
approved by the Institution Ethics Committee. Written
informed consent was obtained from all subjects. We
certify that all applicable institutional and governmental
regulations concerning the ethical use of human
volunteers were followed during this research.
The POAG patients had IOP greater than 21 mmHg,
typical GON with or without visual field defects,
gonioscopy (Goldmann three-mirror lens) disclosing a
3601 normal-appearing open angle, and no apparent
ocular or systemic abnormalities that might account for
the increased IOP. The exclusion criteria included
best-corrected visual acuity (BCVA) of less than 20/80,
any sign of secondary glaucoma, significant media
opacities, and a history of using oral or topical steroids.
Typical GON findings included a vertical cup-to-disc
ratio greater than 0.5, cup-to-disc ratio asymmetry equal
to or greater than 0.2 between eyes, notch and splinter
haemorrhage. Visual-field SAP findings (Humphrey
Swedish Interactive Threshold AlgorithmFStandard
24–2, Carl Zeiss Meditec, Dublin, CA, USA) were
considered suggestive of glaucoma when either defects
of three or more points in cluster with a probability of
less than 5% in a non-edge localization at the pattern
deviation plot were observed, or a pattern standard
deviation index with a probability of less than 5% was
found or a normal outside limit result was obtained in
the glaucoma hemifield test.
Not all patients were receiving antiglaucoma treatment
when included in the study, and they randomly received
timolol maleate 0.5%, brimonidine tartrate 0.2%, or
travoprost 0.004% in one randomly selected eye.
Allocation was based on computer-generated random
numbers and was concealed by using sequentially
numbered opaque sealed envelopes. The examiner
(M.V.P.) responsible for the visual function tests was
masked from the treatment allocation of patients
throughout the study.
All patients underwent BCVA test (Snellen chart),
visual quality perception analysis (visual analogue scale
(VAS)),17 Goldmann applanation tonometry, CS test
(Functional Acuity Contrast Test, Stereo Optical Co,
USA) and SAP in a random sequence at the baseline and
then 4 weeks after glaucoma treatment. The VAS
consisted of a 10-mm horizontal line where the patients
were asked to mark the quality of their vision from 0
(worst possibleFleft extreme) to 10 (best possibleFright
extreme). Both SAP and the CS tests were performed
twice at the baseline evaluation with a 10-min interval.
The second measurement obtained from each
examination was used in the analysis. Patients with IOP
higher than 25 mmHg at baseline were re-examined a
week after starting treatment. Patients with IOP higher
than 21 mmHg, a week after using antiglaucoma
medication, were excluded.
It was calculated that a sample size of 52 individuals
would achieve 80% power to detect a mean change of
1.0 dB in the SAP MD index with an estimated standard
deviation of the change of 2.5 dB and a significance level
of 0.05. The paired t-test and Wilcoxon signed rank test
were used to compare the measurement changes
between the baseline and the 4-week treatment visits.
The Spearman rank correlation test was performed to
analyse the correlation between changes in visual
function exams and IOP. One-way analysis of variance
and the Kruskal–Wallis test were used to compare
measurements obtained from the three treatment groups.
Results
A total of 54 POAG patients were randomly assigned for
the three different types of medication. The recruitment
period started in March 2005 and the last follow-up visit
was in December 2005. At the baseline visit, 18 patients
were allocated to be treated with timolol, 17 with
brimonidine, and 19 with travoprost. A week after
starting the treatment, four patients (one using timolol
and three using brimonidine) were excluded because IOP
was greater than 21 mmHg. All other participants
completed the study, with 17 patients using timolol, 14
using brimonidine, and 19 using travoprost (Table 1).
Four weeks after starting the glaucoma treatment, IOP
(Po0.001), VAS (P¼ 0.045), SAP mean deviation
(P¼ 0.02), and CS frequencies (12 [P¼ 0.03] and 18
[P¼ 0.002] cycles/degree) showed statistically significant
changes (Table 2).
When the three medication groups were compared,
there was no significant difference concerning all
parameters analysed (P40.40) (Table 3). No significant
correlations between IOP and visual function changes
were found (P40.30) (Table 4).
Discussion
In this study, changes in visual function were observed in
glaucoma patients after the start of glaucoma treatment.
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However, these changes were not correlated with IOP
reduction. Previous studies have demonstrated an
improvement of CS with different medications.2,13 Evans
et al2 evaluated 16 POAG patients using brimonidine
or timolol and reported an improvement of CS (6 and
12 cycles/degree) with brimonidine. There were no
significant changes in the group tested with timolol. On
the other hand, in this study, patients using brimonidine
showed a lower mean IOP (22.3 mmHg) and a better
BCVA at baseline. These facts could be related to the
differences found between study results.
Analysing visual function changes after surgical
reduction of IOP, Gandolfi et al4 have described a
significant improvement in CS at frequencies of 3, 6, and
12 cycles/degree. They also observed a moderate to
strong association between CS changes and IOP
reductions at frequencies of 3 (R2¼ 0.67) and 12
(R2¼ 0.43) cycles/degree. The study had a long follow-
up (36 months), and the best threshold of CS was
achieved at 9 months. The 10 patients evaluated had high
IOP (430 mmHg), no visual field defects, and BCVA of
20/20 at baseline. The differences in baseline
Table 1 Baseline characteristics of the patients that completed the study according to the treatment
Variable Timolol Brimonidine Travoprost
Number 17 14 19
Age (years), mean (SD) 56.2 (11.5) 60.9 (13.2) 65.9 (10.9)
Gender (male/female) 7/10 4/10 6/13
Race (black/white) 10/7 6/8 11/8
C/D ratio, mean (SD) 0.7 (0.13) 0.73 (0.15) 0.75 (0.11)
IOP (mmHg), mean (SD) 25.3 (4.9) 24.6 (5.1) 24.5 (3.6)
BCVA (log MAR), mean (SD) 0.18 (0.16) 0.27 (0.22) 0.24 (0.22)
VAS, mean (SD) 6.8 (2.4) 6.5 (1.9) 7.4 (2.2)
SAP
Mean deviation (dB), mean (SD) 6.84 (8.24) 5.45 (4.99) 7.10 (7.13)
Pattern SD (dB), mean (SD) 5.19 (4.11) 5.20 (3.81) 5.17 (3.75)
Contrast sensitivity
1.5 (cycle/degree), mean (SD) 1.63 (0.17) 1.60 (0.23) 1.59 (0.18)
3 (cycles/degree), mean (SD) 1.66 (0.27) 1.55 (0.48) 1.54 (0.44)
6 (cycles/degree), mean (SD) 1.55 (0.29) 1.41 (0.49) 1.30 (0.50)
12 (cycles/degree), mean (SD) 0.94 (0.57) 0.89 (0.60) 0.79 (0.51)
18 (cycles/degree), mean (SD) 0.46 (0.46) 0.46 (0.51) 0.22 (0.34)
BCVA, best-corrected visual acuity; C/D ratio, cup-to-disc ratio; IOP, intraocular pressure; log MAR, logarithmic of minimum angle of resolution; SAP,
standard automated perimetry; SD, standard deviation; VAS, visual analogue scale.
Table 2 Intraocular pressure and visual function at baseline and after treatment including all participants
Variable Baseline mean (SD) After treatment mean (SD) Difference mean (SD) P-value
IOP (mmHg) 24.8 (4.4) 16.9 (4.3) 7.8 (3.6) o0.001a
BCVA (log MAR) 0.23 (0.20) 0.20 (0.19) 0.03 (0.12) 0.06b
VAS 6.96 (2.20) 7.52 (2.01) 0.56 (1.93) 0.045b
SAP
Mean deviation (dB) 6.56 (6.93) 5.72 (6.73) 0.84 (2.45) 0.02a
Pattern SD (dB) 5.19 (3.81) 4.95 (4.01) 0.24 (1.96) 0.26a
Contrast sensitivity
1.5 (cycle/degree) 1.61 (0.19) 1.63 (0.20) 0.02 (0.16) 0.21a
3 (cycles/degree) 1.58 (0.40) 1.65 (0.28) 0.07 (0.28) 0.21a
6 (cycles/degree) 1.42 (0.44) 1.42 (0.52) 0.003 (0.38) 0.24a
12 (cycles/degree) 0.87 (0.55) 0.97 (0.56) 0.10 (0.37) 0.03a
18 (cycles/degree) 0.37 (0.44) 0.55 (0.48) 0.18 (0.42) 0.002a
BCVA, best-corrected visual acuity; IOP, intraocular pressure; log MAR, logarithmic of minimum angle of resolution; SAP, standard automated perimetry;
SD, standard deviation; VAS, visual analogue scale.
aWilcoxon signed rank test.
bPaired t-test.
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measurements, as well as in the follow-up time
between the former study and the present one might
be responsible for the different outcomes observed for
each study.
In our study, POAG patients receiving travoprost
treatment did not present any difference in visual
function changes when compared with patients receiving
the other two medications. Studies with a similar design
using prostaglandin analogues were not found in
literature. Considering other visual function parameters,
no significant changes were observed in the BCVA or
in IOP in this study (mean of 24.8 mmHg) at baseline.
However, this fact does not preclude the possibility of
improvement in patients with higher IOP levels. A
significant difference in the SAP mean deviation index
was found, but not in the pattern standard deviation.
Although different studies describe an improvement of
visual field after reducing IOP in glaucoma eyes,6–8,18 this
improvement has not been reported by other studies.15,16
Heijl et al15 analysed 42 glaucoma eyes after laser
trabeculoplasty and found no reduction of visual field
defects. In relation to the VAS outcomes, most patients
in this study showed better results after glaucoma
treatment. This could be due to either a true
improvement in the visual function or psychological
influence during treatment.
Visual function changes in glaucoma patients have
been the main subject of several studies, and the results
in literature remain controversial.2,4,6,7,13,15,16,18 Some
possible reasons for the discrepancies found among the
studies could be related to sample size, baseline IOP
level, disease stage, treatment modality, as well as
spontaneous fluctuations of the visual field (long-term
fluctuation) and the influence of learning.
The exact mechanism responsible for an improvement
in visual function after glaucoma treatment remains
unknown. Two main possibilities are improvement of
ganglion cell activity and an increase in ocular
perfusion.2,4,13 During the disease process,
subpopulations of cells may be dead, damaged, or
healthy.2 The improvement in visual function reported
here could be due to a recovery of suffering ganglion
cells after a decrease in IOP.2,4,13 In relation to ocular
haemodynamics, previous reports observed better ocular
perfusion with the use of hypotensive medications.19,20
This improvement in microcirculatory conditions was
associated with contrast sensitivity enhancement
in different studies, especially at the frequency of
6 cycles/degree.14,20
Table 3 Changes (after treatment minus baseline) in intraocular pressure and visual function for each treatment group
Variable Timolol mean (SD) Brimonidine mean (SD) Travoprost mean (SD) P-value
IOP (mmHg) 7.8 (3.7) 7.1 (3.8) 8.3 (3.6) 0.69a
BCVA (log MAR) 0.03 (0.07) 0.04 (0.18) 0.04 (0.10) 0.84b
VAS 0.23 (1.75) 0.78 (1.93) 0.68 (2.13) 0.41b
SAP
Mean deviation (dB) 1.01 (2.53) 0.68 (2.70) 0.81 (2.32) 0.93a
Pattern SD (dB) 0.84 (2.44) 0.36 (1.35) 0.14 (1.80) 0.62b
Contrast sensitivity
1.5 (cycle/degree) 0.04 (0.13) 0.04 (0.19) 0.01 (0.16) 0.50b
3 (cycles/degree) 0.08 (0.19) 0.10 (0.30) 0.03 (0.34) 0.49b
6 (cycles/degree) 0.03 (0.28) 0.04 (0.38) 0.01 (0.48) 0.88b
12 (cycles/degree) 0.19 (0.47) 0.07 (0.34) 0.03 (0.28) 0.51b
18 (cycles/degree) 0.26 (0.29) 0.13 (0.38) 0.16 (0.54) 0.41b
BCVA, best-corrected visual acuity; IOP, intraocular pressure; log MAR, logarithmic of minimum angle of resolution; SAP, standard automated perimetry;
SD, standard deviation; VAS, visual analogue scale.
aOne-way analysis of variance.
bKruskal–Wallis test.
Table 4 Correlation between intraocular pressure reduction
and visual function changes including all participants
Visual function rs
a (95% CI) P-value
BCVA 0.01 (0.29 to 0.27) 0.96
VAS 0.07 (0.21 to 0.35) 0.61
SAP
Mean deviation 0.12 (0.17 to 0.38) 0.42
Pattern SD 0.09 (0.19 to 0.36) 0.51
Contrast sensitivity
1.5 (cycle/degree) 0.15 (0.41 to 0.13) 0.30
3 (cycles/degree) 0.07 (0.34 to 0.21) 0.63
6 (cycles/degree) 0.10 (0.18 to 0.37) 0.49
12 (cycles/degree) 0.11 (0.38 to 0.17) 0.45
18 (cycles/degree) 0.14 (0.14 to 0.41) 0.32
BCVA, best-corrected visual acuity; CI, confidence interval; SAP, standard
automated perimetry; SD, standard deviation; VAS, visual analogue scale.
aSpearman rank correlation test.
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Some aspects of this study should be noticed: (1) there
is no control group without treatment, due to ethical
reasons; (2) most excluded patients, due to lack of IOP
control, were on brimonidine, which could bias the
results of this medication; (3) two visual fields at baseline
may not be enough to exclude the learning effect
observed in some patients; (4) the comparison between
the three medications should be interpreted cautiously
due to the limited sample size of each group; (5) in the
light of multiple statistical tests performed, the P-values
should also be cautiously interpreted due to the
possibility of type I error inflation.
In conclusion, this study suggests that patients’ visual
quality perception, SAP mean deviation index, and CS at
higher frequencies improve after starting glaucoma
therapy. However, no correlation was found between IOP
reduction and changes in visual function, and no
differences were found in visual function changes
between the three medications studied.
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